EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES (EEJBS)
ISSN: 2992-4138 ©EEJBS Publications
Volume 6 Issue 3 2025

Nanotechnology for Liquid Biopsy in Cancer: Advances in Early Diagnosis and Real-Time Monitoring

Kamanzi Ntakirutimana G.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide, with early diagnosis and real-time treatment monitoring being pivotal for improved patient outcomes. Liquid biopsy has emerged as a minimally invasive technique that detects cancer-derived biomarkers such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and microRNAs in body fluids. Despite its promise, the sensitivity, specificity, and reproducibility of conventional liquid biopsy methods are limited. Nanotechnology offers transformative potential to overcome these challenges by enabling highly sensitive, specific, and multiplexed detection of cancer biomarkers. Nanomaterials such as gold nanoparticles, magnetic nanoparticles, quantum dots, and carbon-based nanostructures have been engineered for efficient biomarker capture, signal amplification, and real-time molecular profiling. This review highlights recent advances in nanotechnology-enabled liquid biopsy platforms, focusing on their design principles, functional mechanisms, and clinical utility in early cancer detection and treatment monitoring. Furthermore, we discuss ongoing clinical translations, regulatory considerations, and future directions that will determine the integration of nanotechnology-based liquid biopsy into precision oncology.

Keywords: Nanotechnology, Liquid Biopsy, Cancer Diagnosis, Circulating Biomarkers, Real-Time Monitoring

INTRODUCTION

Cancer continues to be a major global health challenge, with millions of new cases diagnosed annually and high mortality rates associated with late detection and treatment resistance[1–3]. Traditional methods of cancer diagnosis, such as tissue biopsy and imaging, although valuable, have significant limitations[4–6]. Tissue biopsies are invasive procedures that often require surgical intervention, which may not be feasible for all patients or tumor locations. Moreover, they provide only a snapshot of the tumor at a single time point and location, failing to capture the dynamic and heterogeneous nature of cancer[7]. As tumors evolve under therapeutic pressure, they may acquire new genetic mutations and exhibit differential expression of biomarkers. Consequently, repeated tissue sampling becomes impractical, posing risks to the patient and often delaying critical treatment decisions.

In this context, liquid biopsy has emerged as a revolutionary tool that offers a minimally invasive alternative for cancer detection and monitoring[8, 9]. Liquid biopsy refers to the analysis of tumor-derived components present in body fluids such as blood, urine, cerebrospinal fluid, and saliva. These components include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vehicles (EVs), microRNAs, and other molecular entities that reflect the tumor's genetic and epigenetic landscape[10]. The ability to detect these biomarkers provides clinicians with a real-time window into the tumor's molecular profile, enabling early diagnosis, assessment of treatment response, detection of minimal residual disease, and monitoring of disease recurrence[10, 11].

However, a major challenge in leveraging the full potential of liquid biopsy lies in the low abundance and instability of these biomarkers in the circulatory system[12]. Tumor-derived molecules are typically present in very small quantities, often masked by a background of normal cellular components, making their accurate detection and quantification technically demanding[12]. Additionally, the transient nature of many of these biomarkers, coupled with the complex biological environment in which they circulate, necessitates the use of highly sensitive and specific analytical tools[13].

This is where nanotechnology has demonstrated transformative potential. Nanotechnology refers to the manipulation and application of materials at the nanometer scale, typically ranging from 1 to 100 nanometers[14]. At this scale, materials exhibit unique physical, chemical, and biological properties that differ markedly from their bulk counterparts. These properties can be exploited to develop novel diagnostic platforms capable of enhancing the sensitivity, specificity, and multiplexing capabilities of liquid biopsy assays[15, 16].

Nanomaterials such as gold nanoparticles, magnetic nanoparticles, quantum dots, carbon nanotubes, and polymeric nanostructures have been extensively investigated for their applications in biomarker detection[17]. These nanostructures can be engineered to selectively bind to cancer biomarkers through surface functionalization with antibodies, aptamers, or other ligands. Once bound, the nanomaterials can amplify the signal through mechanisms such as surface plasmon resonance, fluorescence resonance energy transfer, or magnetic separation, facilitating the detection of trace levels of target molecules[17, 18].

Furthermore, nanotechnology enables the integration of liquid biopsy into portable, point-of-care diagnostic platforms. Microfluidic chips embedded with nanosensors allow rapid sample processing and multiplexed detection in a single assay, significantly reducing turnaround times[19]. This opens new possibilities for real-time molecular diagnostics, enabling dynamic monitoring of tumor evolution and personalized therapy adjustments.

In sum, the convergence of nanotechnology and liquid biopsy is redefining the landscape of cancer diagnostics. By overcoming the limitations of conventional detection methods, nanotechnology-enhanced liquid biopsy offers the promise of earlier cancer detection, improved prognostication, and more effective treatment monitoring. As research in this field continues to evolve, the development of robust, clinically validated nanodiagnostic platforms will be critical in translating this potential into routine clinical practice, ultimately improving patient outcomes and advancing the goals of precision oncology.

2. Cancer Biomarkers in Liquid Biopsy

The success of liquid biopsy hinges on the identification and detection of cancer-associated biomarkers that are shed into body fluids by tumors[20]. These biomarkers serve as surrogates for tumor presence, activity, and progression, offering critical insights into the molecular and cellular events underlying malignancy. Among the most studied biomarkers in liquid biopsy are circulating tumor cells (CTCs), cell-free DNA (cfDNA) including its tumor-derived subset circulating tumor DNA (ctDNA), extracellular vesicles (EVs) such as exosomes, and circulating microRNAs (miRNAs)[21]. Each of these biomarkers provides unique information, yet their detection poses distinct technical challenges that have spurred the integration of nanotechnology into liquid biopsy workflows[21].

Circulating tumor cells (CTCs) are cancer cells that have detached from the primary tumor or metastatic sites and entered the bloodstream[22]. These cells can provide valuable information about the tumor's genetic makeup, metastatic potential, and treatment resistance[22]. However, they are extremely rare, often present as few as one cell per billion blood cells, making their isolation and analysis exceptionally challenging. Conventional methods such as immunomagnetic separation and size-based filtration have limited efficiency and specificity. Nanotechnology offers improved CTC capture through the use of functionalized nanoparticles or nanostructured surfaces that increase binding affinity and enable high-throughput enrichment[23, 24].

Cell-free DNA (cfDNA) comprises short DNA fragments released into the bloodstream primarily through apoptosis and necrosis. A small fraction of cfDNA, known as ctDNA, originates specifically from tumor cells and carries genetic alterations such as point mutations, copy number variations, and methylation patterns reflective of the tumor genome[25]. The detection of ctDNA allows non-invasive genotyping and the monitoring of genetic evolution during therapy. However, ctDNA exists in low concentrations and is easily degraded by nucleases in the bloodstream[26]. Nanoscale biosensors and magnetic nanostructures have been developed to enhance ctDNA isolation and signal detection, increasing analytical sensitivity and improving clinical applicability. Exosomes and other extracellular vesicles (EVs) are nanosized lipid bilayer-enclosed particles secreted by cells, including tumor cells, into the extracellular environment[27, 28]. These vesicles carry a molecular cargo that includes proteins, lipids, DNA, mRNA, and non-coding RNAs, reflective of the cellular state of their origin. In cancer, tumor-derived exosomes play a role in intercellular communication, metastasis, and immune modulation[29]. Their stability in circulation and their ability to protect their molecular contents from degradation make them attractive biomarkers for liquid biopsy. Nanotechnology has enabled the development of exosome isolation platforms based on immunoaffinity capture, microfluidic separation, and nanostructured substrates, facilitating their use in cancer diagnostics[30].

Circulating microRNAs (miRNAs) are short, non-coding RNA molecules that regulate gene expression post-transcriptionally[31]. In cancer, aberrant miRNA expression profiles are associated with oncogenesis, progression, and resistance to therapy. miRNAs are found in biofluids in a stable form, either encapsulated within EVs or bound to proteins such as Argonaute. Despite their stability, the detection of miRNAs at clinically relevant levels remains a challenge due to their small size and sequence similarity[31]. Nanotechnology has

contributed to the development of ultra-sensitive biosensors using nanomaterials such as gold nanoparticles, graphene oxide, and quantum dots to enable precise quantification and multiplexed analysis of cancer-associated miRNAs.

Collectively, these biomarkers hold immense promise for early cancer detection, prognosis, treatment stratification, and surveillance. Yet, the inherent biological complexity and low abundance of these molecules necessitate innovative detection strategies. Nanotechnology not only enhances sensitivity and specificity but also introduces novel platforms for biomarker capture, enrichment, and analysis[31, 32]. The ongoing refinement of these nanoscale tools is crucial for transitioning liquid biopsy from research settings into routine clinical practice, where it can support real-time, personalized, and minimally invasive cancer management.

3. Nanotechnology-Based Platforms for Liquid Biopsy

3.1 Gold Nanoparticles (AuNPs)

Gold nanoparticles (AuNPs) have emerged as one of the most extensively explored nanomaterials in liquid biopsy applications due to their excellent biocompatibility, unique physicochemical properties, and ease of surface modification[33–35]. One of their most distinguishing characteristics is localized surface plasmon resonance (LSPR), which allows them to produce strong and tunable optical signals upon light excitation. This property is particularly advantageous in biosensing platforms where signal intensity can be directly correlated with the presence of specific biomarkers[36]. AuNPs can be functionalized with a variety of biomolecules such as oligonucleotides, aptamers, peptides, or antibodies, which allows them to selectively bind to circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomal proteins. When AuNPs interact with their target biomarker, changes in their aggregation state or the local refractive index can generate measurable colorimetric or fluorescent changes[37]. These features have been exploited in developing rapid and sensitive diagnostic assays that are simple to interpret and often require minimal instrumentation. Additionally, AuNPs can be integrated into lateral flow assays or microfluidic systems for point-of-care diagnostics, offering potential for real-time and non-invasive cancer monitoring. Their ability to act as both diagnostic agents and drug delivery vehicles further enhances their value in theranostic applications[37]. Despite these promising attributes, challenges such as large-scale production, in vivo stability, and potential toxicity at high doses must be addressed before clinical translation is fully realized. Nevertheless, the multifunctionality and tunability of AuNPs continue to position them at the forefront of nanotechnology-driven liquid biopsy innovations.

3.2 Magnetic Nanoparticles (MNPs)

Magnetic nanoparticles (MNPs) have revolutionized the field of liquid biopsy by enabling the rapid, efficient, and selective isolation of tumor-derived biomarkers from complex biological fluids such as blood, urine, or saliva[38–40]. Typically composed of iron oxide (Fe_3O_4 or γ-Fe_2O_3) and coated with biocompatible polymers, MNPs possess superparamagnetic properties, which allow them to respond to external magnetic fields without retaining residual magnetism[41–43]. This feature makes them highly effective for repeated capture and release operations during biomarker isolation. Functionalization of MNPs with targeting ligands such as antibodies, aptamers, or nucleic acid probes allows for the specific capture of circulating tumor cells (CTCs), exosomes, or circulating free DNA (cfDNA). Once bound, these biomarker-loaded nanoparticles can be magnetically separated from the sample matrix within minutes, greatly simplifying sample preparation and enhancing detection sensitivity[44]. Furthermore, the integration of MNPs with microfluidic platforms has led to the development of high-throughput and automated systems capable of processing clinical samples with minimal manual intervention[44]. This integration also facilitates on-chip molecular profiling through downstream analysis such as PCR, sequencing, or immunostaining[45]. MNP-based enrichment strategies are particularly valuable in the context of rare biomarkers, where traditional isolation methods fall short due to low abundance and high background noise. In addition to diagnostic utility, MNPs have potential therapeutic applications, such as magnetically guided drug delivery and hyperthermia treatment. However, issues related to particle aggregation, long-term biocompatibility, and standardization of magnetic properties need to be carefully addressed to ensure reliable clinical adoption[45].

3.3 Quantum Dots (QDs)

Quantum dots (QDs) are semiconductor nanocrystals that exhibit unique optical properties, including high quantum yield, exceptional brightness, and photostability[46–48]. These properties make them ideal candidates for biosensing applications in liquid biopsy, particularly in multiplexed and real-time molecular diagnostics. QDs can be precisely engineered to emit light at specific wavelengths by varying their size and composition, allowing for simultaneous detection of multiple biomarkers within a single assay—a critical advantage in comprehensive cancer profiling[49–51]. Functionalization of QDs with biomolecules such as oligonucleotides, peptides, or antibodies enables specific binding to circulating tumor biomarkers like microRNAs (miRNAs), ctDNA, and exosomal surface proteins. QD-based biosensors often utilize fluorescence resonance energy transfer (FRET) mechanisms to detect molecular interactions, producing a fluorescence signal only upon binding with the target biomarker[50]. This high sensitivity and specificity reduce false-positive rates and

improve early-stage cancer detection. Furthermore, QDs are compatible with various detection modalities, including fluorescence microscopy, flow cytometry, and microfluidic devices, making them versatile tools for both research and clinical settings. Recent advances have explored the use of QDs in smartphone-based diagnostics and point-of-care devices, broadening their accessibility[49]. Despite their potential, concerns remain regarding the long-term toxicity of heavy metals such as cadmium used in many QD formulations. Biocompatible and environmentally safer alternatives, such as silicon or carbon-based QDs, are under development to address this issue. As research progresses, QDs are poised to play an increasingly significant role in personalized cancer diagnostics and real-time biomarker monitoring.

3.4 Carbon Nanostructures (CNTs and Graphene)

Carbon-based nanomaterials, including carbon nanotubes (CNTs) and graphene, offer remarkable electrical, mechanical, and structural properties that are highly advantageous in biosensing applications for liquid biopsy[52]. CNTs cylindrical structures composed of rolled graphene sheets and graphene itself, a single layer of sp^2-bonded carbon atoms arranged in a two-dimensional lattice, both exhibit large surface areas, high electron mobility, and excellent conductivity[53]. These characteristics enable the development of highly sensitive electrochemical and field-effect transistor (FET)-based biosensors capable of detecting ultra-low concentrations of cancer biomarkers such as ctDNA, miRNAs, and exosomal proteins. The high surface-to-volume ratio allows for dense functionalization with capture probes, including DNA oligonucleotides, aptamers, or antibodies, ensuring strong and selective binding to target analytes. Upon target interaction, measurable changes in current or potential can be observed, providing label-free detection with rapid response times[53]. This is particularly useful for real-time monitoring of disease progression or therapeutic response. Moreover, the mechanical flexibility of these nanomaterials makes them suitable for integration into wearable biosensors and lab-on-chip systems. Graphene oxide and reduced graphene oxide variants further offer tunable surface chemistry for improved biocompatibility and sensor performance. Recent innovations have also combined carbon nanostructures with signal amplification strategies or nanocomposites to enhance sensitivity and reduce background interference. However, challenges such as reproducibility in synthesis, toxicity concerns, and integration into scalable diagnostic platforms remain[54]. Nonetheless, CNTs and graphene hold tremendous promise for advancing non-invasive cancer diagnostics, enabling early detection and more effective treatment monitoring.

4. Clinical Applications and Recent Developments

Nanotechnology has revolutionized the field of liquid biopsy, offering advanced tools for the early detection, monitoring, and management of cancer. By enhancing the sensitivity, specificity, and multiplexing capabilities of biomarker detection, nanotechnology-integrated platforms are rapidly gaining clinical relevance.

Early cancer detection is one of the most critical applications of nanotechnology-enhanced liquid biopsy. Traditional diagnostic tools often fail to detect cancer at its earliest stages due to the low abundance of circulating tumor DNA (ctDNA), microRNAs (miRNAs), or exosomal proteins[55]. However, nanoparticle-based assays particularly those using gold nanoparticles (AuNPs), magnetic nanoparticles, or quantum dots, can amplify signals and improve sensitivity, enabling the detection of minute biomolecular changes[55]. This facilitates the identification of early-stage tumors, improving the likelihood of successful treatment outcomes.

In therapy monitoring and resistance profiling**,** nanostructured biosensors allow for the dynamic tracking of ctDNA and circulating tumor cells (CTCs) in response to treatment[56]. By capturing changes in mutation burden or protein expression over time, these sensors can inform clinicians about therapeutic efficacy and emerging drug resistance. This is particularly valuable in the context of precision medicine, where treatment regimens must be adapted in real-time based on tumor evolution[56].

Nanotechnology also plays a vital role in minimal residual disease (MRD) detection, an area where traditional imaging and biopsy techniques often fall short[57]. Nanoparticle-enhanced detection systems are capable of identifying residual tumor-derived components in circulation even when clinical signs of disease are absent, guiding decisions on adjuvant therapy and improving relapse prevention.

Furthermore, multiplexed biomarker analysis is made possible through platforms that integrate various nanomaterials, such as liposomes, polymeric nanoparticles, and carbon-based nanostructures[58]. These platforms can simultaneously detect multiple classes of biomarkers DNA, RNA, proteins, thereby enhancing diagnostic precision and providing a comprehensive tumor profile from a single sample.

Commercially, systems like **Guardant360**, an FDA-approved ctDNA assay, have set the benchmark, while newer nanotechnology-driven devices are progressing through clinical trials[59]. The fusion of nanotechnology with microfluidics and AI analytics holds enormous promise for expanding clinical applications in oncology and beyond.

5. Challenges and Future Perspectives

Despite the remarkable progress in the development of nanotechnology-enhanced liquid biopsy tools, several critical challenges remain that hinder widespread clinical translation and adoption. A major issue is

biocompatibility and safety. While many nanomaterials offer impressive functional properties, some exhibit potential toxicity or immunogenicity. Their long-term accumulation in tissues and unclear metabolic clearance pathways raise safety concerns. Therefore, extensive in vivo studies and toxicological assessments are necessary to ensure that these materials are safe for repeated or chronic use in human patients.

Another obstacle lies in standardization and scalability. The synthesis of nanomaterials often involves complex and variable fabrication protocols that can affect particle size, surface characteristics, and functionalization. Lack of standardized protocols makes it difficult to reproduce results across different laboratories and hinders the establishment of quality control benchmarks. To enable clinical utility, consistent manufacturing practices and validated assay protocols must be developed and regulated.

Regulatory and ethical hurdles also present formidable barriers. Current regulatory frameworks were not designed for nanotechnology-based diagnostics, creating uncertainty around approval processes. Moreover, ethical considerations related to data security, privacy, and equitable access to advanced diagnostics must be addressed. This is especially crucial in low-resource settings, where technological disparity could exacerbate healthcare inequalities.

Looking ahead, the integration of nanotechnology with artificial intelligence (AI) offers exciting potential. AI can analyze complex datasets generated from multiplexed nanoparticle assays, identifying predictive biomarker patterns and enabling personalized treatment strategies. Furthermore, the development of wearable nanosensors could enable continuous, real-time health monitoring, shifting cancer diagnostics from periodic testing to proactive surveillance.

Finally, the concept of personalized nanodiagnostics, where nanodevices are engineered using patient-specific molecular profiles, could revolutionize precision oncology. This approach would allow the tailoring of diagnostic platforms to an individual's unique tumor biology, thereby optimizing therapeutic decisions. In conclusion, while nanotechnology holds transformative potential for liquid biopsy, multidisciplinary efforts across nanoscience, clinical oncology, regulatory science, and bioethics are essential to overcome existing challenges and fully realize its clinical promise.

CONCLUSION

Nanotechnology has revolutionized the field of liquid biopsy, offering unprecedented capabilities in sensitivity, specificity, and multiplexing. By enabling non-invasive, real-time tracking of cancer biomarkers, nanotechnology-based liquid biopsy holds the potential to transform cancer diagnosis, prognosis, and therapy monitoring. Continued interdisciplinary collaboration, clinical validation, and regulatory support will be key to harnessing its full potential in precision oncology.

REFERENCES

1. Abdullah, K.M., Sharma, G., Singh, A.P., Siddiqui, J.A.: Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside. Mol. Cancer. 24, 169 (2025). https://doi.org/10.1186/s12943-025-02368-w
2. Tufail, T., Uti, D.E., Aja, P.M., Offor, C.E., Ibiam, U.A., Ukaidi, C.U.A.: Utilizing Indigenous Flora in East Africa for Breast Cancer Treatment: An Overview. Anticancer Agents Med. Chem. 25, 99–113 (2025). https://doi.org/10.2174/0118715206338557240909081833
3. Obisi, J.N., Abimbola, A.N.J., Babaleye, O.A., Atidoglo, P.K., Usin, S.G., Nwanaforo, E.O., Patrick-Inezi, F.S., Fasogbon, I.V., Chimezie, J., Dare, C.A., Kuti, O.O., Uti, D.E., Omeoga, H.C.: Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations. Discov. Oncol. 16, 373 (2025). https://doi.org/10.1007/s12672-025-02102-4
4. Hashimoto, K., Nishimura, S., Ito, T., Oka, N., Akagi, M.: Limitations and usefulness of biopsy techniques for the diagnosis of metastatic bone and soft tissue tumors. Ann. Med. Surg. 68, 102581 (2021). https://doi.org/10.1016/j.amsu.2021.102581
5. Zafar, A., Khatoon, S., Khan, M.J., Abu, J., Naeem, A.: Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov. Oncol. 16, 607 (2025). https://doi.org/10.1007/s12672-025-02198-8
6. Alum, E.U.: AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis. Discov. Oncol. 16, 313 (2025). https://doi.org/10.1007/s12672-025-02064-7
7. Gromek, P., Senkowska, Z., Płuciennik, E., Pasieka, Z., Zhao, L.-Y., Gielecińska, A., Kciuk, M., Kłosiński, K., Kałuzińska-Kołat, Ż., Kołat, D.: Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods. World J. Methodol. 14, 92982 (2024). https://doi.org/10.5662/wjm.v14.i2.92982
8. Pandey, S., Yadav, P.: Liquid biopsy in cancer management: Integrating diagnostics and clinical applications. Pract. Lab. Med. 43, e00446 (2025). https://doi.org/10.1016/j.plabm.2024.e00446

9. Mukerjee, N., Alharbi, H.M., Maitra, S., Anand, K., Thorat, N., Gorai, S.: Exosomes in liquid biopsy and oncology: Nanotechnological interplay and the quest to overcome cancer drug resistance. J. Liq. Biopsy. 3, (2024). https://doi.org/10.1016/j.jlb.2023.100134
10. Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., Wei, J.: Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct. Target. Ther. 9, 336 (2024). https://doi.org/10.1038/s41392-024-02021-w
11. Wang, X., Wang, L., Lin, H., Zhu, Y., Huang, D., Lai, M., Xi, X., Huang, J., Zhang, W., Zhong, T.: Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front. Oncol. 14, 1303335 (2024). https://doi.org/10.3389/fonc.2024.1303335
12. Coppola, C.A., Summa, S.D., Matera, G., Pilato, B., Traversa, D., Tommasi, S.: Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology. Int. J. Mol. Sci. 26, 5013 (2025). https://doi.org/10.3390/ijms26115013
13. Davis, K.D., Aghaeepour, N., Ahn, A.H., Angst, M.S., Borsook, D., Brenton, A., Burczynski, M.E., Crean, C., Edwards, R., Gaudilliere, B., Hergenroeder, G.W., Iadarola, M.J., Iyengar, S., Jiang, Y., Kong, J.-T., Mackey, S., Saab, C.Y., Sang, C.N., Scholz, J., Segerdahl, M., Tracey, I., Veasley, C., Wang, J., Wager, T.D., Wasan, A.D., Pelleymounter, M.A.: Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat. Rev. Neurol. 16, 381–400 (2020). https://doi.org/10.1038/s41582-020-0362-2
14. Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B., Pecho, R.D.C., Jayasankar, N., Rao, D.P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M.J., Amajd, A., Abo-Zaid, M.A., Castillo-Acobo, R.Y., Ismail, A.H., Amin, A.H., Akhavan-Sigari, R.: Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol. Cancer. 22, 169 (2023). https://doi.org/10.1186/s12943-023-01865-0
15. Olawade, D.B., Ige, A.O., Olaremu, A.G., Ijiwade, J.O., Adeola, A.O.: The synergy of artificial intelligence and nanotechnology towards advancing innovation and sustainability - A mini-review. Nano Trends. 8, 100052 (2024). https://doi.org/10.1016/j.nwnano.2024.100052
16. Khatoon, U.T., Velidandi, A.: An Overview on the Role of Government Initiatives in Nanotechnology Innovation for Sustainable Economic Development and Research Progress. Sustainability. 17, 1250 (2025). https://doi.org/10.3390/su17031250
17. Malik, S., Singh, J., Goyat, R., Saharan, Y., Chaudhry, V., Umar, A., Ibrahim, A.A., Akbar, S., Ameen, S., Baskoutas, S.: Nanomaterials-based biosensor and their applications: A review. Heliyon. 9, e19929 (2023). https://doi.org/10.1016/j.heliyon.2023.e19929
18. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
19. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
20. Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., Wei, J.: Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct. Target. Ther. 9, 336 (2024). https://doi.org/10.1038/s41392-024-02021-w
21. Yin, H., Zhang, M., Zhang, Y., Zhang, X., Zhang, X., Zhang, B.: Liquid biopsies in cancer. Mol. Biomed. 6, 18 (2025). https://doi.org/10.1186/s43556-025-00257-8
22. Rapanotti, M.C., Cenci, T., Scioli, M.G., Cugini, E., Anzillotti, S., Savino, L., Coletta, D., Di Raimondo, C., Campione, E., Roselli, M., Bernardini, S., Bianchi, L., De Luca, A., Ferlosio, A., Orlandi, A.: Circulating Tumor Cells: Origin, Role, Current Applications, and Future Perspectives for Personalized Medicine. Biomedicines. 12, 2137 (2024). https://doi.org/10.3390/biomedicines12092137
23. Bashir, S., Amn Zia, M., Shoukat, M., Kaleem, I., Bashir, S.: Nanoparticles as a novel key driver for the isolation and detection of circulating tumour cells. Sci. Rep. 14, 22580 (2024). https://doi.org/10.1038/s41598-024-67221-4
24. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
25. Swarup, N., Leung, H.Y., Choi, I., Aziz, M.A., Cheng, J.C., Wong, D.T.W.: Cell-Free DNA: Features and Attributes Shaping the Next Frontier in Liquid Biopsy. Mol. Diagn. Ther. 29, 277–290 (2025). https://doi.org/10.1007/s40291-025-00773-x

26. Stejskal, P., Goodarzi, H., Srovnal, J., Hajdúch, M., van 't Veer, L.J., Magbanua, M.J.M.: Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol. Cancer. 22, 15 (2023). https://doi.org/10.1186/s12943-022-01710-w
27. Liu, Z., Pang, B., Wang, Y., Zheng, J., Li, Y., Jiang, J.: Advances of New Extracellular Vesicle Isolation and Detection Technologies in Cancer Diagnosis. Small. 21, 2405872 (2025). https://doi.org/10.1002/smll.202405872
28. Lee, M., Kim, J., Jang, M., Park, C., Lee, J.-H., Lee, T.: Introduction of Nanomaterials to Biosensors for Exosome Detection: Case Study for Cancer Analysis. Biosensors. 12, 648 (2022). https://doi.org/10.3390/bios12080648
29. Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., Fang, X., Zhang, X.: Exosomes as a new frontier of cancer liquid biopsy. Mol. Cancer. 21, 56 (2022). https://doi.org/10.1186/s12943-022-01509-9
30. Tang, H., Yu, D., Zhang, J., Wang, M., Fu, M., Qian, Y., Zhang, X., Ji, R., Gu, J., Zhang, X.: The new advance of exosome-based liquid biopsy for cancer diagnosis. J. Nanobiotechnology. 22, 610 (2024). https://doi.org/10.1186/s12951-024-02863-0
31. Woolard, E., Chorley, B.N.: Chapter 3-1 - The Role of Noncoding RNAs in Gene Regulation. In: McCullough, S.D. and Dolinoy, D.C. (eds.) Toxicoepigenetics. pp. 217–235. Academic Press (2019)
32. Zhang, Y., Li, M., Gao, X., Chen, Y., Liu, T.: Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J. Hematol. Oncol.J Hematol Oncol. 12, 137 (2019). https://doi.org/10.1186/s13045-019-0833-3
33. Arcos Rosero, W.A., Bueno Barbezan, A., Daruich de Souza, C., Chuery Martins Rostelato, M.E.: Review of Advances in Coating and Functionalization of Gold Nanoparticles: From Theory to Biomedical Application. Pharmaceutics. 16, 255 (2024). https://doi.org/10.3390/pharmaceutics16020255
34. Codullo, V., Cova, E., Pandolfi, L., Breda, S., Morosini, M., Frangipane, V., Malatesta, M., Calderan, L., Cagnone, M., Pacini, C., Cavagna, L., Recalde, H., Distler, J.H.W., Giustra, M., Prosperi, D., Colombo, M., Meloni, F., Montecucco, C.: Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. J. Control. Release Off. J. Control. Release Soc. 310, 198–208 (2019). https://doi.org/10.1016/j.jconrel.2019.08.015
35. Karnwal, A., Kumar Sachan, R.S., Devgon, I., Devgon, J., Pant, G., Panchpuri, M., Ahmad, A., Alshammari, M.B., Hossain, K., Kumar, G.: Gold Nanoparticles in Nanobiotechnology: From Synthesis to Biosensing Applications. ACS Omega. 9, 29966–29982 (2024). https://doi.org/10.1021/acsomega.3c10352
36. Mcoyi, M.P., Mpofu, K.T., Sekhwama, M., Mthunzi-Kufa, P.: Developments in Localized Surface Plasmon Resonance. Plasmonics. (2024). https://doi.org/10.1007/s11468-024-02620-x
37. Millozzi, F., Milán-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzarán, M., Sandonà, M., Rodríguez-Díaz, C., Martínez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M.T., Bouché, M., Parolini, O., Saccone, V., Toulmé, J.-J., Somoza, Á., Palacios, D.: Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nat. Commun. 16, 577 (2025). https://doi.org/10.1038/s41467-024-55223-9
38. Anderson, S.D., Gwenin, V.V., Gwenin, C.D.: Magnetic Functionalized Nanoparticles for Biomedical, Drug Delivery and Imaging Applications. Nanoscale Res. Lett. 14, 188 (2019). https://doi.org/10.1186/s11671-019-3019-6
39. Nassireslami, E., Ajdarzade, M.: Gold Coated Superparamagnetic Iron Oxide Nanoparticles as Effective Nanoparticles to Eradicate Breast Cancer Cells via Photothermal Therapy. Adv. Pharm. Bull. 8, 201–209 (2018). https://doi.org/10.15171/apb.2018.024
40. Okeke, I.S., Echeweozo, E.O., Ogu, A.C., Aondona, P.Y., Ezema, F.I.: Iron oxide Nanoparticles; A Review on the role of Transition Metal doping on its magnetic properties and particle size for imaging and therapeutic applications. Hybrid Adv. 7, 100322 (2024). https://doi.org/10.1016/j.hybadv.2024.100322
41. Chauhan, P., Kumar, D., Sharma, R.: Biogenic magnetic iron oxide nanoparticles for multifunctional applications in environmental remediation and biomedical field. J. Environ. Chem. Eng. 13, 115646 (2025). https://doi.org/10.1016/j.jece.2025.115646
42. Rahman, M.: Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine. Nanotheranostics. 7, 424–449 (2023). https://doi.org/10.7150/ntno.86467
43. Nguyen, M.D., Tran, H.-V., Xu, S., Lee, T.R.: Fe3O4 Nanoparticles: Structures, Synthesis, Magnetic Properties, Surface Functionalization, and Emerging Applications. Appl. Sci. 11, 11301 (2021). https://doi.org/10.3390/app112311301
44. Kajani, A.A., Rafiee, L., Samandari, M., Mehrgardi, M.A., Zarrin, B., Javanmard, S.H.: Facile, rapid and efficient isolation of circulating tumor cells using aptamer-targeted magnetic nanoparticles integrated with a microfluidic device. RSC Adv. 12, 32834–32843. https://doi.org/10.1039/d2ra05930d

45. Molinski, J., Tadimety, A., Burklund, A., Zhang, J.X.J.: Scalable signature-based molecular diagnostics through on-chip biomarker profiling coupled with machine learning. Ann. Biomed. Eng. 48, 2377–2399 (2020). https://doi.org/10.1007/s10439-020-02593-y
46. Bao, H., Liu, Y., Li, H., Qi, W., Sun, K.: Luminescence of carbon quantum dots and their application in biochemistry. Heliyon. 9, e20317 (2023). https://doi.org/10.1016/j.heliyon.2023.e20317
47. Henna, T.K., Pramod, K.: Graphene quantum dots redefine nanobiomedicine. Mater. Sci. Eng. C. 110, 110651 (2020). https://doi.org/10.1016/j.msec.2020.110651
48. Martins, C.S.M., LaGrow, A.P., Prior, J.A.V.: Quantum Dots for Cancer-Related miRNA Monitoring. ACS Sens. 7, 1269–1299 (2022). https://doi.org/10.1021/acssensors.2c00149
49. Sarkar, K., Bank, S., Chatterjee, A., Dutta, K., Das, A., Chakraborty, S., Paul, N., Sarkar, J., De, S., Ghosh, S., Acharyya, K., Chattopadhyay, D., Das, M.: Hyaluronic acid-graphene oxide quantum dots nanoconjugate as dual purpose drug delivery and therapeutic agent in meta-inflammation. J. Nanobiotechnology. 21, 246 (2023). https://doi.org/10.1186/s12951-023-02015-w
50. Singh, S., Dhawan, A., Karhana, S., Bhat, M., Dinda, A.K.: Quantum Dots: An Emerging Tool for Point-of-Care Testing. Micromachines. 11, 1058 (2020). https://doi.org/10.3390/mi11121058
51. Costa, M.C.F., Echeverrigaray, S.G., Andreeva, D.V., Novoselov, K.S., Neto, A.H.C.: Two-Dimensional Quantum Dots: From Photoluminescence to Biomedical Applications. Solids. 3, 578–602 (2022). https://doi.org/10.3390/solids3040037
52. Fathi-karkan, S., Nasiri, S., Hasannia, M., Rahdar, A., Nouri, M., Najafi, M., Basiri, A., Tehrani, F.S., Hashemi, S.M., Romanholo Ferreira, L.F.: Green carbon dots and theranostic applications. J. Drug Deliv. Sci. Technol. 108, 106861 (2025). https://doi.org/10.1016/j.jddst.2025.106861
53. Ferrier, D.C., Honeychurch, K.C.: Carbon Nanotube (CNT)-Based Biosensors. Biosensors. 11, 486 (2021). https://doi.org/10.3390/bios11120486
54. Nautiyal, D., Jain, U.: Emerging Trends in Fluorescent and Quenching Nanomaterials for Viral detection: Innovations in Biological and Chemical sensing. Talanta Open. 11, 100430 (2025). https://doi.org/10.1016/j.talo.2025.100430
55. Batool, S.M., Yekula, A., Khanna, P., Hsia, T., Gamblin, A.S., Ekanayake, E., Escobedo, A.K., You, D.G., Castro, C.M., Im, H., Kilic, T., Garlin, M.A., Skog, J., Dinulescu, D.M., Dudley, J., Agrawal, N., Cheng, J., Abtin, F., Aberle, D.R., Chia, D., Elashoff, D., Grognan, T., Krysan, K., Oh, S.S., Strom, C., Tu, M., Wei, F., Xian, R.R., Skates, S.J., Zhang, D.Y., Trinh, T., Watson, M., Aft, R., Rawal, S., Agarwal, A., Kesmodel, S.B., Yang, C., Shen, C., Hochberg, F.H., Wong, D.T.W., Patel, A.A., Papadopoulos, N., Bettegowda, C., Cote, R.J., Srivastava, S., Lee, H., Carter, B.S., Balaj, L.: The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Rep. Med. 4, 101198 (2023). https://doi.org/10.1016/j.xcrm.2023.101198
56. Kumar, S., Poria, R., Kala, D., Nagraik, R., Dhir, Y., Dhir, S., Singh, B., Kaushik, N.K., Noorani, M.S., Kumar, D., Gupta, S., Kaushal, A.: Recent advances in ctDNA detection using electrochemical biosensor for cancer. Discov. Oncol. 15, 517 (2024). https://doi.org/10.1007/s12672-024-01365-7
57. Sim, S., Wong, N.K.: Nanotechnology and its use in imaging and drug delivery (Review). Biomed. Rep. 14, 42 (2021). https://doi.org/10.3892/br.2021.1418
58. Zou, S., Peng, G., Ma, Z.: Surface-Functionalizing Strategies for Multiplexed Molecular Biosensing: Developments Powered by Advancements in Nanotechnologies. Nanomaterials. 14, 2014 (2024). https://doi.org/10.3390/nano14242014
59. Zhong, H.-J., Zhen, Y., Chen, S., Shi, W., Liang, X., Yang, G.-J.: Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care. Breast Cancer Res. BCR. 27, 97 (2025). https://doi.org/10.1186/s13058-025-02024-7

CITE AS: Kamanzi Ntakirutimana G. (2025). Nanotechnology for Liquid Biopsy in Cancer: Advances in Early Diagnosis and Real-Time Monitoring. EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES 6(3):37-44